Jove
Visualize
联系我们

相关概念视频

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

865
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
865
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

669
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
669
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

37
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
37
Angina IV: Management01:26

Angina IV: Management

22
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
22

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Insights into the Thermal Degradation Kinetics of β-Lactam Antibiotics: A Comparative Study of Cefazolin, Ceftriaxone, and Meropenem.

Antibiotics (Basel, Switzerland)·2026
Same author

Clinical Characteristics, Risk Score Distribution, and Hospitalization Status in Emergency Department Patients with Acute Chest Pain: A Single-Center Retrospective Four-Year Study.

Clinics and practice·2026
Same author

Cumulative Frameworks as a Pragmatic Alternative to Multivariable Modeling in Rare-Event Clinical Settings: A Coronary Care Unit Case Study.

Methods and protocols·2026
Same author

Decoding Cyclodextrins in Skin Applications: Structure, Mechanisms, and Safety in Cosmetic and Dermatologic Formulations (Part I).

International journal of molecular sciences·2026
Same author

Redox-active copper(II) complexes with mixed heterocyclic N-donor ligands as dual antimicrobial and anti-tumor agents.

European journal of medicinal chemistry·2026
Same author

New Insights into the Antimicrobial and Wound-Healing Properties of Turmeric-Powder-Derived <i>Curcuma longa</i> Extracts for Oral-Health-Oriented Applications.

Biomedicines·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Sep 9, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

对高胆固醇血症管理的最新方法的全面审查:传统和新型治疗方法的比较分析:第二部分

Narcisa Jianu1,2, Ema-Teodora Nițu1,2,3, Cristina Merlan2

  • 1Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timișoara, Romania.

Pharmaceuticals (Basel, Switzerland)
|August 28, 2025
PubMed
概括

新药疗法为治疗高胆固醇和降低心血管疾病风险提供了新的希望. 这些先进的治疗针对高残留风险或他类药物不耐受症患者的特定途径.

关键词:
PCSK9 抑制剂的使用贝佩多酸降低心血管疾病的风险治疗脱脂症的新兴方法高胆固醇血症其他类型降脂疗法其他:

更多相关视频

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.2K

相关实验视频

Last Updated: Sep 9, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.2K

科学领域:

  • 心脏病学
  • 药理学
  • 遗传学

背景情况:

  • 心血管疾病 (CVD) 是全球主要的死亡原因,高胆固醇是关键可改变的危险因素.
  • 之前的审查涵盖了脂质代谢,动脉样硬化,并发症,风险评估和常规疗法 (他类药物,ezetimibe).

研究的目的:

  • 审查新兴的药物治疗方法来治疗脱脂症.
  • 对高残留心血管风险,家族性高胆固醇血症或他类药物不耐受症的患者探索新药.

主要方法:

  • 对新药的机制,临床应用,安全性和药物遗传学的审查.
  • 关注PCSK9抑制剂,siRNA治疗,ACL抑制剂,MTP抑制剂和ANGPTL3抑制剂.

主要成果:

  • 新型药物如PCSK9抑制剂,英克利西兰,贝佩多酸,洛米塔皮德和埃维纳库马布提供了针对性的治疗选择.
  • 这些疗法解决了标准治疗的局限性,为特定的患者群体提供了替代方案.

结论:

  • 新兴的疗法扩大了脂质障碍症的治疗范围,使得患者可以得到更个性化的护理.
  • 精准医学的进步对于优化治疗策略和改善心血管结果至关重要.